All News

Viral/Non-Viral Vectors

Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells
8 March 2023
Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells
Are you looking to engineer
Avectas Launches Solupore® Non-Viral Platform for Engineering Cells at Advanced Therapies Week
18 January 2023
Avectas Launches Solupore® Non-Viral Platform for Engineering Cells at Advanced Therapies Week
The Solupore® platform looks to
ReiThera Opens New Large-Scale Viral Vector Manufacturing Facility
10 January 2023
ReiThera Opens New Large-Scale Viral Vector Manufacturing Facility
Leading contract development and manufacturing
5 Things to Consider when Sourcing Plasmids
15 December 2022
5 Things to Consider when Sourcing Plasmids
Dr Katie Roberts presents 5
POPULAR NEWS ITEMS
Image
23 March 2023

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image
14 March 2023

Pfizer Invests $43 Billion to Acquire Seagen

Image
2 March 2023

Early Adoption and Partnerships – The Secret to Commercialization Success?

What to Look for in a Transient AAV Platform
15 December 2022
What to Look for in a Transient AAV Platform
Dr Katie Roberts explores 4
A Novel Technology for AAV Manufacture: TESSA™ in the Spotlight
15 December 2022
A Novel Technology for AAV Manufacture: TESSA™ in the Spotlight
Over the past year or
Manufacturing the Future of Accessible Gene Therapy
21 November 2022
Manufacturing the Future of Accessible Gene Therapy
For this Editorial, Dr Katie
FDA Releases Guidelines for Multiple Version Cell and Gene Therapy Early-Phase Trials
15 November 2022
FDA Releases Guidelines for Multiple Version Cell and Gene Therapy Early-Phase Trials
The FDA has released finalized
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image

Pfizer Invests $43 Billion to Acquire Seagen

Image

Early Adoption and Partnerships – The Secret to Commercialization Success?